Unexpectedly, the CCL2 had no significant effects on the proliferation or the trastuzumab resistance of NCI-N87 and KATO III cells when culturing tumor cells alone (online supplemental figure 2A, B), suggesting the tumor cell-derived CCL2 had no direct effect to promote the tumor progression via an autocrine pathway. The gene discussed is CCL2; the disease is neoplasm.